Survivin expression in renal cell carcinoma

Cancer Investigation

Volumn 26, Issue 9, 2008, Pages 929-935

  Zamparese, Rosanna ^a   Pannone, Giuseppe ^a   Santoro, Angela ^a   Muzio, Lorenzo Lo ^a   Corsi, Fabrizio ^a   Pedicillo, Maria C ^a   Scillitani, Ester L ^a   Tortorella, Simona ^a   Staibano, Stefania ^b   Piscuoglio, Salvatore ^b   Russo, Lucio Lo ^a   Bufo, Pantaleo ^a,c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SC Anatomia Patologica Universitaria ^*  (Italy)

Author keywords

Disease specific survival; Programmed cell death; Renal clear cell carcinoma; Survivin

Indexed keywords

SURVIVIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL PROTOCOL; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 57049102388     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802017553     Document Type: Article

References (45)

1. Stenzl, A.; deKernion, J.B. Pathology, biology, and clinical staging of renal cell carcinoma. Semin Oncol 1989, 16, 3-11.
2. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M.J. Cancer statistics, 2005. CA Cancer J Clin 2005, 55, 10-30.
3. Lohse, C.M.; Cheville, J.C. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 2005, 25 (2), 433-464.
4. Curti, B.D. Renal cell carcinoma. JAMA 2004, 292 (1), 97-100.
5. Buzaid, A.C.; Todd, M.B. Therapeutic options in renal cell carcinoma. Semin Oncol 1989, 16 (1 Suppl 1), 12-9.
6. Ljungberg, B.; Alamdari, F.I.; Rasmuson, T.; Roos, G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999, 84(4), 405-11.
7. Levy, D.A.; Slaton, J.W.; Swanson, D.A.; Dinney, C.P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998, 159(4), 1163-1167.
8. Figlin, R.A.; Pierce, W.C.; Kaboo, R.; Tso, C.L.; Moldawer, N.; Gitlitz, B.; deKernion, J.; Belldegrun, A. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997, 158(3 Pt 1), 740-745.
9. Frank, I.; Blute, M. L.; Cheville, J. C.; Lohse, C. M.; Weaver, A. L.; Zincke, H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168(6), 2395-2400.
10. Sengupta, S.; Lohse, C.M.; Leibovich, B.C.; Frank, I.; Thompson, R.H.; Webster, W.S.; Zincke, H.; Blute, M.L.; Cheville, J.C.; Kwon, E.D. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005, 104(3), 511-520.
11. Leibovich, B.C.; Blute, M.L.; Cheville, J.C.; Lohse, C.M.; Frank, I.; Kwon, E.D.; Weaver, A.L.; Parker, A.S.; Zincke, H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97(7), 1663-1671.
12. Zisman, A.; Pantuck, A.J.; Dorey, F.; Said, J.W.; Shvarts, O.; Quintana, D.; Gitlitz, B.J.; deKernion, J.B.; Figlin, R.A.; Belldegrun, A.S. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19(6), 1649-1657.
13. Mejean, A.; Oudard, S.; Thiounn, N. Prognostic factors of renal cell carcinoma. J Urol 2003, 169(3), 821-827.
14. Siminovitch, J.M.; Montie, J.E.; Straffon, R.A. Prognostic indicators in renal adenocarcinoma. J Urol 1983, 130(1), 20-23.
15. Medeiros, L.J.; Gelb, A.B.; Weiss, L.M. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988, 61(8), 1639-1651.
16. Yagoda, A. Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol 1989, 7(4), 199-206.
17. Strohmeyer, T.; Ackermann, R. Classic and modern prognostic indicators in renal cell carcinoma. Review of the literature. Urol Int 1991, 47(4), 203-212.
18. Mrstik, C.; Salamon, J.; Weber, R.; Stogermayer, F. Microscopic venous infiltration as predictor of relapse in renal cell carcinoma. J Urol 1992, 148(2 Pt 1), 271-274.
19. Deveraux, Q.L.; Reed, J.C. IAP family proteins-suppressors of apoptosis. Genes Dev 1999, 13(3), 239-252.
20. Salvesen, G.S.; Duckett, C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3(6), 401-410.
21. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3(8), 917-921.
22. Altieri, D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001, 7(12), 542-547.
23. Greener, F., AJCC Cancer Staging Manual. Editor. 2002, Springler-Verlag: New York.
24. Delahunt, B.; Kittelson, J.M.; McCredie, M.R.; Reeve, A.E.; Stewart, J.H.; Bilous, A.M. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 2002, 94(3), 658-664.
25. Erdogan, F.; Demirel, A.; Polat, O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract 2004, 58(4), 333-336.
26. Grossman, D.; McNiff, J.M.; Li, F.; Altieri, D.C. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999, 79(9), 1121-1126.
27. Grossman, D.; Kim, P.J.; Blanc-Brude, O.P.; Brash, D.E.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001, 108(7), 991-999.
28. Mahotka, C.; Wenzel, M.; Springer, E.; Gabbert, H.E.; Gerharz, C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999, 59(24), 6097-6102.
29. Mahotka, C.; Liebmann, J.; Wenzel, M.; Suschek, C.V.; Schmitt, M.; Gabbert, H.E.; Gerharz, C.D. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002, 9(12), 1334-1342.
30. Mahotka, C.; Krieg, T.; Krieg, A.; Wenzel, M.; Suschek, C.V.; Heydthausen, M.; Gabbert, H.E.; Gerharz, C.D. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002, 100(1), 30-36.
31. Reed, J.C. Dysregulation of apoptosis in cancer. J Clin Oncol 1999, 17(9), 2941-2953.
32. Fortugno, P.; Wall, N.R.; Giodini, A.; O'Connor, D.S.; Plescia, J.; Padgett, K.M.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002, 115(Pt 3):575-585.
33. Dohi, T.; Beltrami, E.; Wall, N.R.; Plescia, J.; Altieri, D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004, 114(8):1117-1127.
34. Sohn, D.M.; Kim, S.Y.; Baek, M.J.; Lim, C.W.; Lee, M.H.; Cho, M.S.; Kim, T.Y. Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 2006, 60(6), 289-292.
35. Lo Muzio, L.; Pannone, G.; Staibano, S.; Mignogna, M.D.; Rubini, C.; Mariggio, M.A.; Procaccini, M.; Ferrari, F.; De Rosa, G.; Altieri, D.C. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003, 89(12), 2244-2248.
36. Huang, Y.; Park, Y.C.; Rich, R.L.; Segal, D.; Myszka, D.G.; Wu, H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 2001, 104(5), 781-790.
37. Srinivasula, S.M.; Gupta, S.; Datta, P.; Zhang, Z.; Hegde, R.; Cheong, N.; Fernandes-Alnemri, T.; Alnemri, E.S. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem 2003, 278(34), 31469-31472.
38. Yan, Y.; Mahotka, C.; Heikaus, S.; Shibata, T.; Wethkamp, N.; Liebmann, J.; Suschek, C.V.; Guo, Y.; Gabbert, H.E.; Gerharz, C.D.; Ramp, U. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer 2004, 91(7), 1349-1357.
39. Kosari, F.; Parker, A.S.; Kube, D.M.; Lohse, C.M.; Leibovich, B.C.; Blute, M.L.; Cheville, J.C.; Vasmatzis, G. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005, 11(14), 5128-5139.
40. Parker, A.S.; Kosari, F.; Lohse, C.M.; Houston Thompson, R.; Kwon, E.D.; Murphy, L.; Riehle, D.L.; Blute, M.L.; Leibovich, B.C.; Vasmatzis, G.; Cheville, J.C. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006, 107(1), 37-45.
41. Krambeck, A.E.; Dong, H.; Thompson, R.H.; Kuntz, S.M.; Lohse, C.M.; Leibovich, B.C.; Blute, M.L.; Sebo, T.J.; Cheville, J.C.; Parker, A.S.; Kwon, E.D. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 2007, 13(6), 1749-1756.
42. Byun, S.S.; Yeo, W.G.; Lee, S.E.; Lee, E. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 2007, 69(1), 34-37.
43. Glinsky, G.V.; Glinsky, V.V.; Ivanova, A.B.; Hueser, C.J. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 1997, 115(2), 185-193.
44. Glinsky, G.V.; Glinsky, V.V. Apoptosis amd metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 1996, 101(1), 43-51.
45. Reed, J.C.; Wilson, D.B. Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003, 9(17), 6310-6315.